SM
MRTX

Sabby Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Sabby Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-193
Closed -$2.83M – 201
2021
Q4 		$2.83M Hold
193
– – 0.41% 37
2021
Q3 		$3.41M Hold
193
– – 0.46% 28
2021
Q2 		$3.12M Buy
193
+48
+33% +$7.71K 0.44% 27
2021
Q1 		$2.48M Hold
145
– – 0.48% 40
2020
Q4 		$3.19M Buy
+145
New +$31.3K 0.61% 28

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sabby Management's MRTX Position: Q4 2021 in Review

Sabby Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 5,000 shares — an estimated $776K sold.

Sabby Management first reported a position in MRTX in Q4 2013 and held it in 13 quarters. The position peaked at $2.06M in Q3 2015. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

  • Sabby Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Sabby Management sold 5,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $776K.
  • Sabby Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2013 and held it in 13 quarters.
  • Sabby Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.06M in Q3 2015.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.